Moderna stock price could surge another 45% on COVID-19 vaccine - Business Insider

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 51%

United States News News

United States United States Latest News,United States United States Headlines

Moderna is poised to surge another 45% in the next year, COVID-19 vaccine could generate more than $5 billion in annual sales, Jefferies says

is set to surge higher even after its epic 220% rally so far this year, according to Jefferies.

The bullish rating hinges on Moderna's COVID-19 vaccine working and resulting in large government supply contracts, Jefferies equity analyst Michael Yee wrote in a Monday note. In the first full year of sales of its potential vaccine, Jefferies' model shows it could bring in $2 billion worldwide if roughly 50 million people get the vaccine at $50. This could grow to a peak of $5 billion between 2025 and 2026, according to the note.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

English press release of Dr. Zelenko new study. Please share. Treat early and live. Combo works.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 729. in US

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

ICU head in Bergamo, Italy, says COVID-19 causing 'chronic damage' - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Source: BusinessInsider - 🏆 729. / 51 Read more »